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Abstract: The present study is part of the genetic mapping of Indonesia focusing on drug metabolizing 
enzymes, which started with the Buginese population of Makassar, South Sulawesi. The two CYP450 
gene subfamilies, i.e. CYP2C9 and CYP2C19 are of interest as they exhibit wide inter-individual vari-
ation in expression, which influence the drug metabolism capacity. The CYP2C9 alleles of interest in this 
study were CYP2C9*2 and *3, and of CYP2C19 was CYP2C19*17. The study aimed to determine the frequencies of the 
CYP2C9 genotype, which contains *1, *2 and *3 alleles, and the CYP2C19 genotype, which comprises the *1 and *17 alleles 
in the Buginese. Ninety six Buginese subjects, comprising 48 males and 48 females were studied. CYP2C9 and CYP2C19 al-
leles were detected by a PCR-RFLP assay method. Results showed that there was no CYP2C9*2 allele present, while the fre-
quencies of CYP2C9*3 and CYP2C19*17 overall were 1.56 % and 4.68 %, respectively. The frequency of the CYP2C9*3 
allele in females was 2.08%, and not statistically different from that in males (1.05%). The frequency of the CYP2C19*17 
allele in females (8.33%), was significantly different (P<0.05) from that in males (1.05%). No subject carried the 
CYP2C9*2/*2, CYP2C9*3/*3, CYP2C19*17/*17, or CYP2C9*3/CYP2C19*17 genotype. The study is the first to describe 
the drug metabolizing enzyme polymorphisms, CYP2C9 and CYP2C19, in the Indonesian Buginese population. 
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1. INTRODUCTION 
 Genetic polymorphisms of drug metabolizing enzymes 
are one of the major determinants of inter-individual 
variability in drug response and are becoming a rapidly 
growing field in pharmacogenetics [1-3]. The cytochrome 
P450 (CYP450) family are the primary metabolic pathway 
for the metabolism of most drugs. The two CYP2C subfami-
lies, i.e. CYP2C9 and CYP2C19, exhibit wide inter-
individual variation in expression that affects drug metabo-
lism capacity [4]. Among these functional variants, 
CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910) have 
been extensively studied. The CYP2C9*2 allele encodes a 
moderately defective protein whereas the CYP2C9*3 allele 
has lower af nity and markedly lower intrinsic clearance for 
numerous drugs, both in vitro and in vivo [5]. These alleles 
have reduced catalytic activity compared to that of the wild 
type CYP2C9*1 [6]. The reduced activity may decrease the 
clearance of the parent drug and therefore increase its tox-
icity. In the case of CYP2C19, the variant allele of interest is 
CYP2C19*17 (rs12248560). This allele is associated with an 
increase in transcription rate and drug metabolism compared 
to those seen in the wild type CYP2C19*1 [7], and this  
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results in a lack of response to the parent drug due to its low 
availability. In contrast, it causes an extensive response when 
the parent drug is activated to the more active metabolites by 
this enzyme (as in prodrug). CYP2C9 and CYP2C19 variant 
alleles show considerable variation across different ethnic 
and continental populations [7-9]. 
 The archipelago of Indonesia consists of hundreds of 
different ethnic groups. Sulawesi, is located near the Wallace 
line, which marks the transtition zone between Asia and the 
Australia continent. Sulawesi, therefore, has different flora, 
fauna, and also ethnic diversity, compared to other islands 
within Indonesia. One ethnic group in Sulawesi is the 
Buginese. Buginese is the third biggest ethnic in Indonesia, 
after Javanese and Sundanese which may have specific 
physical features and a socio-culture compared to other 
ethnic groups in Indonesia [10]. To date, however, there is 
still a lack of data on polymorphism in the CYP450 genes in 
Indonesians. This paper is one of the first to focus on the 
polymorphism of CYP450 in Indonesia, especially on the 
distribution and frequency of CYP2C9 and CYP2C19 vari-
ants in Buginese population. 
2. MATERIALS AND METHODS 
2.1. Samples 
 Blood samples were taken from 96 healthy subjects of 
Buginese ancestry, consisting of 48 males and 48 females. 
Informed consent was obtained from all subjects and the 
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study protocol was approved by the Ethics Committee of 
Faculty of Medicine, Universitas Gadjah Mada. DNA sam-
ples were prepared from 200 ?l of blood using 20% Chelex 
(Bio-Rad) following the manufacturer’s instructions, then 
stored at -4oC until genotyping was performed. 
2.1. Genotyping Strategy 
 The genotyping strategies involved polymerase chain 
reaction (PCR) and restriction fragment length polymorph-
ism (RFLP) analysis, based on previously developed tech-
niques for CYP2C9 and CYP2C19 genes [11, 12], with 
modification in the primer sequences. The primers were de-
signed to contain a mismatch site to generate the digestion 
site of the respective restriction enzyme. This digestion site 
was disrupted if the subject DNA contained the mutation.  
 The CYP2C9*2 allele results from a C?T mutation at 
the 416 nucleotide position in exon 3 (11). The forward 
primer, 5’-TTTGGGATGGGGAAGAGGAGCATTGGGTA 
C(C?T)-3’, and the reverse primer, 5’-GCTAACAACC 
AGACTCATAATGAAAGA-3’, were designed utilising two 
mismatches to generate the digestion site of the Kpn1 en-
zyme, if the sample is wild type. The digestion site is de-
stroyed if the sample contains the C?T mutation. The am-
plicon is 198 base pairs (bp) in size. Following PCR and 
digestion by the Kpn1 enzyme homozygotes for the wild 
type allele (*1/*1) will be seen as a fragment of 168 bp, 
homozygotes for the CYP2C9*2 allele (*2/*2) will not con-
tain the Kpn1 site, and so a fragment of 198 bp will be seen, 
and heterozygotes (*1/*2) will display fragment sizes of  
168 bp and 198 bp.  
 The CYP2C9*3 allele results from an A?C mutation at 
the 1061 nucleotide position in exon 7 (11). The forward 
primer 5’-CCCCTGAATTGCTACAACAAATGTGCC-3’ and 
the reverse primer 5’-CATGGGGCAGGCTGG TGGGGA-
GAAGATTAA(T?G)-3’ were designed utilising two mis-
matches to generate the digestion site of the Vsp1 enzyme, if 
the sample is wild type. The site is destroyed if the sample 
contains the A?C mutation. The amplicon is 213 bp in size. 
Following PCR and digestion with the Vsp1 enzyme homo-
zygotes for the wild type allele (*1/*1) will be seen as a 
fragment of 183 bp, homozygotes for the CYP2C9*3 allele 
(*3/*3) will not contain the Vsp1 site, and so will be seen as 
a fragment of 213 bp, and heterozygotes (*1/*3) will display 
fragments of 183 bp and 213 bp. 
 The detection of CYP2C19*17 allele was carried out 
using a forward primer, 5’-GGTTCTATTT AATGTGAA 
GCC-3’ and a reverse primer, 5’- TGGCGCATTATCTCTT 
ACATCAGACAT-3’. This is a novel strategy whereby there 
is a mismatch in the reverse primer (mismatch occurs 24 
bases from 5’end of primer) to introduce a Hsp9211 diges-
tion site if DNA is wild type, resulting in a 153 bp fragment. 
If DNA has the CYP2C19*17 mutation, then the Hsp9211 
site is destroyed and the 177 bp fragment will be seen after 
digestion with the Hsp9211 enzyme. 
3. RESULTS  
 The CYP2C9 and CYP2C19 alleles as well as the 
genotype frequencies in the Buginese population are 
summarized in Table 1. No individuals carried the 
CYP2C9*2 allele, three individuals were heterozygous 
2C9*1/*3, no subject was homozygous 2C9*3/*3, and nine 
were heterozygous 2C19*1/*17. The CYP2C19*17/*17 and 
CYP2C9*3/*17 allele was absent in the Buginese. There was 
no CYP2C9*2 allele in the sample, while the frequency of 
the CYP2C9*3 and CYP2C19*17 allele in the Buginese was 
1.56 % and 4.68 %, respectively. The allele frequency of 
CYP2C9*3 was 1.05% in males and was not significantly 
different from that (2.08%) seen in females. On the other 
hand, the frequency of CYP2C19*17 in females was 8.33% 
which was significantly greater than that seen in males 
(1.05%), (P<0.05). Under Hardy-Weinberg equilibrium con-
ditions one homozygotefor CYP2C9*3 is expected in every 
5000 Buginese, whereas, one homozygote for CYP2C19*17 
is expected in every 476 Buginese.  
Table 1. Allele (A) and genotype (B) frequencies of CYP2C9 




Males (%) Females 
(%) 
P-value 
CYP2C9*1 98.95 97.92  
CYP2C9*2 0 0 - 
CYP2C9*3 1.05 2.08 0.557 
CYP2C19*1 98.95 91.67  
CYP2C19*17 1.05 8.33 0.014 
 
B 
Genotype Male Female 
 N (%) (N) (%) 
CYP2C9*1/*1 47 97.92 46 95.83 
CYP2C9*1/*2 0 0 0 0 
CYP2C9*2/*2 0 0 0 0 
CYP2C9*1/*3 1 2.08 2 4.17 
CYP2C9*3/*3 0 0 0 0 
CYP2C19*1/*1 47 97.92 40 83.33 
CYP2C19*1/*17 1 2.08 8 16.67 
CYP2C19*17/*17 0 0 0 0 
CYP2C19*3/*17 0 0 0 0 
 
4. DISCUSSION 
 Our genotyping approach was designed for the utilization 
of inexpensive and commercially available digestion en-
zymes. In order to improve the genotyping, one of each 
primer pairs was designed to incorporate a restriction endo-
nuclease digestion site at its 3’ end, and each primer was 
designed to be around 30 bp in length, which ensured a large 
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enough difference in band size to easily differentiate be-
tween wild type alleles and those with mutations of CYP2C9 
and CYP2C19 genes when run on a 3% agarose gel.  
 These results are novel, as ethnic groups from Indonesia 
have not previously been assessed for CYP450 status. The 
data showed a similar general trend as that seen for other 
Asian groups, namely, a negligible frequency of CYP2C9*2, 
and the presence of the CYP2C9*3 allele at a frequency be-
tween 2%-5% [9, 13, 14]. This observation is in line with the 
report that the CYP2C9*2 allele is primarily restricted to 
European, Middle Eastern and Central/South Asian popula-
tions, but is absent or found at very low frequencies in other 
geographic regions (Africa, East Asia, Oceania and 
America). The CYP2C9*3 allele has a broader geographic 
distribution, but the highest allele frequencies are also found 
in European and Central/South Asian populations [15]. 
 In the case of CYP2C19, we only found heterozygous 
2C19*1/*17, individuals, and no homozygous 2C19*17/*17. 
These data are also similar to that of other Asian 
populations, especially Korean and Chinese [7, 8]. The 
prevalence of the CYP2C19*17 allele was very low [16], 
which therefore has no association with adverse clinical out-
comes after percutaneous coronary intervention and clopi-
dogrel. On the contrary, the CYP2C19*17 allele was found 
in a relatively high frequency in European population, 
especially Greeks, in which it was reported at 19.61% [17]. 
 There is ongoing debate about the health consequences of 
such polymorphisms as those studied here. It is possible that 
they may be associated with adverse clinical outcomes for 
patients taking medications whose metabolism is controlled by 
the products of these genes. This is especially the case for pa-
tients taking drugs with a narrow therapeutic range (warfarin, 
theophylline, digoxin), and saturable kinetics (phenytoin), 
where small alterations in plasma levels may result in dispro-
portionate toxicity [11, 18] or when taking other drugs which 
may have CYP450 inducing or inhibiting properties [19, 20]. 
 The polymorphism also has implications for drug dose 
adjustment. Tentative estimates of how CYP2C9 genotyping 
might be applied to dose adjustments in clinical therapy were 
based on dose-related pharmacokinetic parameters, specially 
the clearance or trough drug concentrations. Mean clearances 
in homozygous carriers of the *3 allele were below 25% of 
that of the wild type for S -warfarin, tolbutamide, glipizide, 
celecoxib, and fluvastatin. In the more frequent heterozygote 
(genotype *1/*3), the clearances were between 40% and 
75%. In these cases in which individual dosages are derived 
from clinical drug effects, such as for the oral anticoagulants, 
the pharmacogenetics-based dose adjustments showed a 
good correlation with the genotype-specific empirically de-
rived doses [21]. 
 In the case of polymorphism in CYP2C19, examples of 
clinical consequences are linked to clopidogrel, a pro drug. 
Carriers of the CYP2C19*2 loss-of-function allele present 
higher platelet reactivity and worse clinical outcomes com-
pared to that seen in non-carriers. The hyper-function allele 
CYP2C19*17 increases the biotransformation of clopidogrel 
to its active metabolite, which in turn increase the effect to 
inhibit platelet aggregation. The simultaneous occurrence of 
the CYP2C19*17 polymorphism seems to offset the negative 
impact of the CYP2C19*2 polymorphism on platelet aggre-
gation [22]. For other drugs, like escitalopram, the homozy-
gous CYP2C19*17 genotype is associated with lower serum 
concentration of escitalopram, which might imply an in-
creased risk of therapeutic failure in psychiatric patients [23]. 
 Such clinical issues highlight the importance of pharma-
cogenomic screening. Further, wider application of such 
testing is being advocated in order to establish whether inter 
individual variation in metabolic capacity exists between 
participants in clinical trials [24], a factor which could influ-
ence outcomes of these studies and subsequent acceptance or 
rejection of new therapeutic substances. 
CONCLUSION 
 The study is the first to describe the genetic polymorphism 
of drug metabolizing enzymes, CYP2C9 and CYP2C19, in an 
Indonesian population. The findings are similar to those seen 
in other Asian populations, especially Korean and Chinese, 
and contribute to genetic polymorphism mapping of drug 
metabolizing enzymes in Asian population. 
LIST OF ABBREVIATIONS 
CYP450 = Cytochrome P450 
PCR = Polymerase chain reaction 
RFLP = Restriction fragment length polymorphism 
ETHICS STATEMENT 
 Study protocol was approved by the Ethics Committee of 
Faculty of Medicine, Universitas Gadjah Mada. 
CONFLICT OF INTEREST 
 The authors confirm that this article content has no con-
flict of interest. 
ACKNOWLEDGEMENTS 
 The authors wish to thank Prof. Nasrum Massi from 
Hasanuddin University for DNA isolation of samples, The 
Ministry of Education for financial support and Muhammad 
Novrizal Abdi Sahid for assistance in writing. 
REFERENCES 
[1] Bae J, Kim H, Kim J, et al. Allele and genotype frequencies of 
CYP2C9 in a Korean population. Br J Clin Pharmacol 2005; 
60(Suppl 4): 418-22. 
[2] Ingelman-Sundberg M, Sim SC. Pharmacogenetic biomarkers as 
tools for improved drug therapy: Emphasis on the cytochrome 
P450 system. Biochem Biophys Res Commun 2010; 396: 90-4. 
[3] Ingelman-Sundberg M. Human drug metabolising cytochrome 
P450 enzymes: Properties and polymorphisms. Naunyn 
Schmiedebergs Arch Pharmacol 2004; 369: 89-104. 
[4] Xie H , Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: 
ethnic distribution and functional significance. Adv Drug Deliver 
Rev 2002; 54: 1257-70. 
[5] Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome 
P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77(1): 1-16. 
[6] Miners JO, Birkett DJ. Cytochrome P4592C9: An enzyme of major 
importance in human drug metabolism. Br J Clin Pharmacol 1998; 
46: 525-38. 
[7] Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 
gene variant causes ultrarapid drug metabolism relevant for the 
Allele Frequency Distributions of the Drug Metabolizer Genes Current Pharmacogenomics and Personalized Medicine, 2014, Vol. 12, No. 4    239 
drug response to proton pump inhibitors and antidepressants. Clin 
Pharmacol Ther 2006; 79: 103-13. 
[8] Yang ZF, Cui HW, Hasi T, et al. Genetic polymorphisms of 
cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian 
population in China. Genet Mol Res 2010; 9 (Suppl 3): 1844-51. 
[9] Yoon Y, Shon J, Kim M, et al. Frequency of Cytochrome P450 
2C9 Mutant Aleles in a Korean Population. Br J Clin Pharmacol 
2001; 51: 277-80. 
[10] Pelras C. Manusia Bugis. Jakarta: Penerbit Nalar (Translation) 
2006. 
[11] Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 
CYP2C9 polymorphisms on warfarin sensitivity and risk of over-
anticoagulation in patients on long-term treatment. Blood 2000; 96: 
1816-9. 
[12] Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-
function polymorphism is a major determinant of clopidogrel re-
sponsiveness in healthy subjects. Blood 2006; 108: 2244-7. 
[13] Xu H, Murray M, McLachlan A. Influence of Genetic Polymorph-
isms on the Pharmacokinetics and Pharmacodynamics of Sulfony-
lurea drugs. Curr Drug Metab 2009; 10: 643-58. 
[14] Zhou S, Liu J, Chowbay B. Polymorphisms of human cytochrome 
P450 enzymes and its clinical impact. Drug Metab Rev 2009; 
41(Suppl 2): 89-295. 
[15] Ross KA, Bigham AW, Edwards M, et al. World allele frequency 
distribution of four polymorphisms associated with warfarin dose 
requirements. J Hum Genet 2010; 55: 582-9. 
[16] Park MW, Her SH, Kim HS, et al. Impact of the CYP2C19*17 
polymorphism on the clinical outcome of clopidogrel therapy in 
Asian patients undergoing percutaneous coronary intervention. 
Pharmacogenet Genomics 2013; (Suppl 10): 558-62. 
[17] Ragia G, Arvanitidis KI, Tavridou A, et al. Need for reassessment 
of reported CYP2C19 allele frequencies in various populations in 
view of CYP2C19*17 discovery: The case of Greece. 
Pharmacogenomics 2009; 10: 43-9. 
[18] Hung CC, Lin CJ, Chen CC, et al. Dosage recommendation of 
phenytoin for patients with epilepsy with different CYP2C9/ 
CYP2C19 polymorphisms. Ther Drug Monit 2004; 26: 534-40. 
[19] Hummel MA, Locuson CW, Gannett PM, et al. CYP2 genotype-
dependent effects on in vitro drug-drug interactions: Switching of 
benzbromarone effect from inhibition to activation in the 
CYP2C9.3 variant. Mol Pharmacol 2005; 68: 644-51. 
[20] Lynch T, Price A. The effect of cytochrome P450 metabolism on 
drug response, interactions, and adverse effects. Am Fam Physician 
2007; 76: 391-6. 
[21] Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome 
P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77(1): 1-16. 
[22] Déry U, Tourigny E, Roy M, et al. Cytochrome P450 2C19*17 
polymorphism offsets the negative effect of 2C19*2 polymorphism 
on platelet reactivity in patients treated with clopidogrel, Canadian 
Cardiovacular Society Meeting, October 2011 
[23] Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact 
of the ultrarapid CYP2C19*17 allele on serum concentration of 
escitalopram in psychiatric patients. Clin Pharmacol Ther 2008; 
83(2): 322-7.  
[24] Van den Anker JN. Do we need to incorporate pharmacogenetics in 
randomised, controlled trials of frequently used medicines? Pediat-
rics 2007; 120: 237. 
 
 
Received: December 16, 2014     Revised: April 8, 2015         Accepted: April 10, 2015 
